-transparent.png){kind=logo}
OBJECTIVE The pharmacokinetics of meloxicam have been studied following administration of a single 15-mg capsule to 12 patients with end-stage renal failure. Pharmacokinetic parameters were determined after haemodialysis. The pharmacokinetic profile obtained in these patients is compared to data obtained from age- and gender-matched healthy volunteers. RESULTS Total plasma meloxicam concentrations were lower in patients with end-stage renal failure (AUC0-infinity 12.6 micrograms.h.ml-1) in comparison with healthy volunteers (AUC0-infinity 39.3 micrograms.h.ml-1). This was reflected by an increase in total clearance (+211%). However, there was an enhanced free meloxicam fraction (unbound drug) in the end-stage renal failure patients (0.9% vs. 0.3% in healthy volunteers). This was observed in association with raised free Cmax (5.0 vs. 2.6 ng/ml) but similar free AUC0-infinity (0.13 vs. 0.11 microgram.h.ml-1) in both groups. Therefore, the raised free fraction is compensated for by the increased total clearance such that no accumulation of meloxicam occurs. Meloxicam plasma concentrations were similar before and after haemodialysis. CONCLUSIONS Meloxicam has displayed a pharmacokinetic profile in end-stage renal failure which is similar to that observed for other highly protein bound nonsteroidal anti-inflammatory drugs (NSAIDs). However, in view of the higher free Cmax value, and despite no evidence of accumulation, it may be prudent to treat this group of patients with a 7.5-mg dose of meloxicam. This is the lower dose normally recommended for adults. Meloxicam is not dialysable.
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
July 1998,
AIDS (London, England),
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
May 1988,
Clinical pharmacology and therapeutics,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
November 2005,
The Journal of pharmacy and pharmacology,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
October 2012,
Clinical pharmacokinetics,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
January 2001,
Yao xue xue bao = Acta pharmaceutica Sinica,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
August 1984,
British journal of anaesthesia,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
May 1998,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
January 1997,
British journal of clinical pharmacology,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
September 1988,
The Journal of antimicrobial chemotherapy,
D Türck, and
A Schwarz, and
D Höffler, and
H H Narjes, and
G Nehmiz, and
G Heinzel
January 1990,
Therapeutic drug monitoring,
